1
|
Eksteen C, Riedemann J, Rass AM, du Plessis M, Botha MH, van der Merwe FH, Engelbrecht AM. A Review: Genetic Mutations as a Key to Unlocking Drug Resistance in Cervical Cancer. Cancer Control 2024; 31:10732748241261539. [PMID: 38881031 PMCID: PMC11181891 DOI: 10.1177/10732748241261539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2024] [Revised: 04/29/2024] [Accepted: 05/27/2024] [Indexed: 06/18/2024] Open
Abstract
Cervical cancer is the fourth most common cancer in women. Advanced stage and metastatic disease are often associated with poor clinical outcomes. This substantiates the absolute necessity for high-throughput diagnostic and treatment platforms that are patient and tumour specific. Cervical cancer treatment constitutes multimodal intervention. Systemic treatments such as chemotherapy and/or focal radiotherapy are typically applied as neoadjuvant and/or adjuvant strategies. Cisplatin constitutes an integral part of standard cervical cancer treatment approaches. However, despite initial patient response, de novo or delayed/acquired treatment resistance is often reported, and toxicity is of concern. Chemotherapy resistance is associated with major alterations in genomic, metabolomic, epigenetic and proteomic landscapes. This results in imbalanced homeostasis associated with pro-oncogenic and proliferative survival, anti-apoptotic benefits, and enhanced DNA damage repair processes. Although significant developments in cancer diagnoses and treatment have been made over the last two decades, drug resistance remains a major obstacle to overcome.
Collapse
Affiliation(s)
- Carla Eksteen
- CancerCare, Cape Gate Oncology Centre, Cape Town, South Africa
| | | | - Atarah M Rass
- Department of Physiological Sciences, Faculty of Science, University of Stellenbosch, Stellenbosch, South Africa
| | - Manisha du Plessis
- Department of Physiological Sciences, Faculty of Science, University of Stellenbosch, Stellenbosch, South Africa
| | - Matthys H Botha
- Department of Obstetrics and Gynecology, Stellenbosch University, Stellenbosch, South Africa
| | | | - Anna-Mart Engelbrecht
- Department of Physiological Sciences, Faculty of Science, University of Stellenbosch, Stellenbosch, South Africa
- African Cancer Institute (ACI), Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa
| |
Collapse
|
2
|
Watanabe T, Soeda S, Okoshi C, Fukuda T, Yasuda S, Fujimori K. Landscape of somatic mutated genes and inherited susceptibility genes in gynecological cancer. J Obstet Gynaecol Res 2023; 49:2629-2643. [PMID: 37632362 DOI: 10.1111/jog.15766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2023] [Accepted: 07/26/2023] [Indexed: 08/28/2023]
Abstract
Traditionally, gynecological cancers have been classified based on histology. Since remarkable advancements in next-generation sequencing technology have enabled the exploration of somatic mutations in various cancer types, comprehensive sequencing efforts have revealed the genomic landscapes of some common forms of human cancer. The genomic features of various gynecological malignancies have been reported by several studies of large-scale genomic cohorts, including The Cancer Genome Atlas. Although recent comprehensive genomic profiling tests, which can detect hundreds of genetic mutations at a time from cancer tissues or blood samples, have been increasingly used as diagnostic clinical biomarkers and in therapeutic management decisions, germline pathogenic variants associated with hereditary cancers can also be detected using this test. Gynecological cancers are closely related to genetic factors, with approximately 5% of endometrial cancer cases and 20% of ovarian cancer cases being caused by germline pathogenic variants. Hereditary breast and ovarian cancer syndrome and Lynch syndrome are the two major cancer susceptibility syndromes among gynecological cancers. In addition, several other hereditary syndromes have been reported to be associated with gynecological cancers. In this review, we highlight the genes for somatic mutation and germline pathogenic variants commonly seen in gynecological cancers. We first describe the relationship between clinicopathological attributes and somatic mutated genes. Subsequently, we discuss the characteristics and clinical management of inherited cancer syndromes resulting from pathogenic germline variants in gynecological malignancies.
Collapse
Affiliation(s)
- Takafumi Watanabe
- Department of Obstetrics and Gynecology, Fukushima Medical University, Fukushima, Japan
| | - Shu Soeda
- Department of Obstetrics and Gynecology, Fukushima Medical University, Fukushima, Japan
| | - Chihiro Okoshi
- Department of Obstetrics and Gynecology, Fukushima Medical University, Fukushima, Japan
| | - Toma Fukuda
- Department of Obstetrics and Gynecology, Fukushima Medical University, Fukushima, Japan
| | - Shun Yasuda
- Department of Obstetrics and Gynecology, Fukushima Medical University, Fukushima, Japan
| | - Keiya Fujimori
- Department of Obstetrics and Gynecology, Fukushima Medical University, Fukushima, Japan
| |
Collapse
|
3
|
Olwal CO, Fabius JM, Zuliani-Alvarez L, Eckhardt M, Kyei GB, Quashie PK, Krogan NJ, Bouhaddou M, Bediako Y. Network modeling suggests HIV infection phenocopies PI3K-AKT pathway mutations to enhance HPV-associated cervical cancer. Mol Omics 2023; 19:538-551. [PMID: 37204043 PMCID: PMC10524288 DOI: 10.1039/d3mo00025g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/20/2023]
Abstract
Women coinfected with human immunodeficiency virus type 1 (HIV-1) and human papillomavirus (HPV) are six times as likely to develop invasive cervical carcinoma compared to those without HIV. Unlike other HIV-associated cancers, the risk of cervical cancer development does not change when HPV/HIV coinfected women begin antiretroviral therapy, suggesting HIV-associated immune suppression is not a key driver of cervical cancer development in coinfected women. Here, we investigated whether the persistent secretion of inflammatory factors in HIV-positive patients on antiretroviral therapy could enhance cancer signaling in HPV-infected cervical cells via endocrine mechanisms. We integrated previously reported HIV-induced secreted inflammatory factors (Hi-SIFs), HIV and HPV virus-human protein interactions, and cervical cancer patient genomic data using network propagation to understand the pathways underlying disease development in HPV/HIV coinfection. Our results pinpointed the PI3K-AKT signaling pathway to be enriched at the interface between Hi-SIFs and HPV-host molecular networks, in alignment with PI3K pathway mutations being prominent drivers of HPV-associated, but HIV independent, cervical cancer development. Furthermore, we experimentally stimulated cervical cells with 14 Hi-SIFs to assess their ability to activate PI3K-AKT signaling. Strikingly, we found 8 factors (CD14, CXCL11, CXCL9, CXCL13, CXCL17, AHSG, CCL18, and MMP-1) to significantly upregulate AKT phosphorylation (pAKT-S473) relative to a phosphate buffered saline control. Our findings suggest that Hi-SIFs cooperate with HPV infection in cervical cells to over-activate PI3K-AKT signaling, effectively phenocopying PI3K-AKT pathway mutations, resulting in enhanced cervical cancer development in coinfected women. Our insights could support the design of therapeutic interventions targeting the PI3K-AKT pathway or neutralizing Hi-SIFs in HPV/HIV coinfected cervical cancer patients.
Collapse
Affiliation(s)
- Charles Ochieng' Olwal
- West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), University of Ghana, Accra, Ghana.
- Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana
| | - Jacqueline M Fabius
- The J. David Gladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA
- Quantitative Biosciences Institute, University of California, San Francisco, CA, USA
- The Cancer Cell Map Initiative, San Francisco and La Jolla, CA, USA
| | - Lorena Zuliani-Alvarez
- The J. David Gladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA
- Quantitative Biosciences Institute, University of California, San Francisco, CA, USA
- The Cancer Cell Map Initiative, San Francisco and La Jolla, CA, USA
- Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA.
| | - Manon Eckhardt
- The J. David Gladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA
- Quantitative Biosciences Institute, University of California, San Francisco, CA, USA
- Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA.
| | - George Boateng Kyei
- Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra, Ghana
- University of Ghana Medical Centre, University of Ghana, Accra, Ghana
| | - Peter Kojo Quashie
- West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), University of Ghana, Accra, Ghana.
| | - Nevan J Krogan
- The J. David Gladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA
- Quantitative Biosciences Institute, University of California, San Francisco, CA, USA
- The Cancer Cell Map Initiative, San Francisco and La Jolla, CA, USA
- Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA.
| | - Mehdi Bouhaddou
- Quantitative Biosciences Institute, University of California, San Francisco, CA, USA
- Institute for Quantitative and Computational Biosciences (QCBio), University of California, Los Angeles, LA, USA
- Department of Microbiology, Immunology, and Molecular Genetics (MIMG), University of California, Los Angeles, LA, USA.
- Molecular Biology Institute, University of California, Los Angeles, LA, USA
| | - Yaw Bediako
- West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), University of Ghana, Accra, Ghana.
- Yemaachi Biotech, Accra, Ghana
| |
Collapse
|
4
|
Sun G, Zhang Q, Liu Y, Xie P. Role of Phosphatidylinositol 3-Kinase and Its Catalytic Unit PIK3CA in Cervical Cancer: A Mini-Review. Appl Bionics Biomech 2022; 2022:6904769. [PMID: 36046780 PMCID: PMC9420646 DOI: 10.1155/2022/6904769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2022] [Revised: 07/15/2022] [Accepted: 07/22/2022] [Indexed: 11/17/2022] Open
Abstract
In complicated disorders like cancer, signaling pathways form a tangled network. Targeting one gene may result in an unfavorable reaction from another off-target gene. Such entwined complexities may result in treatment resistance or failure in cancer patients. The PI3K/Akt/mTOR (phosphoinositol 3-kinase/protein kinase B/mammalian target of rapamycin) pathway is dysregulated in cervical cancer and is used as a biomarker for therapy. PI3K is a kinase that consists of a regulatory and catalytic domain and has phosphorylation capability. Class I components like the catalytic part (PIK3CA and PIK3CD) and regulatory part (like PIK3R1, PIK3R2, PIK3R3, and PIK3R5) are associated with oncogenesis and growth factors in cervical cancer. This review is aimed at discussing the involvement of the PI3K component of the PI3K/Akt/mTOR network in cervical cancer. Specifically, class I catalytic subunit PIK3CA has been identified as a pharmacological target, making it therapeutically significant. Apart from discussing the function of PI3K and PIK3CA in cervical cancer, we also discuss their inhibitors, which may be beneficial in treating cervical cancer.
Collapse
Affiliation(s)
- Guojuan Sun
- Ward Section of Home Overseas Doctors, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China
| | - Qiang Zhang
- Ward Section of Home Overseas Doctors, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China
| | - Yi Liu
- Maternity Rehabilitation Center, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China
| | - Ping Xie
- Ward Section of Home Overseas Doctors, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China
| |
Collapse
|
5
|
Characterization of the Genomic Landscape in Cervical Cancer by Next Generation Sequencing. Genes (Basel) 2022; 13:genes13020287. [PMID: 35205332 PMCID: PMC8871541 DOI: 10.3390/genes13020287] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2021] [Revised: 01/12/2022] [Accepted: 01/26/2022] [Indexed: 12/12/2022] Open
Abstract
Cervical cancer is the fourth leading cause of cancer-related deaths in women worldwide. Although many sequencing studies have been carried out, the genetic characteristics of cervical cancer remain to be fully elucidated, especially in the Asian population. Herein, we investigated the genetic landscape of Chinese cervical cancer patients using a validated multigene next generation sequencing (NGS) panel. We analyzed 64 samples, consisting of 32 tumors and 32 blood samples from 32 Chinese cervical cancer patients by performing multigene NGS with a panel targeting 571 cancer-related genes. A total of 810 somatic variants, 2730 germline mutations and 701 copy number variations (CNVs) were identified. FAT1, HLA-B, PIK3CA, MTOR, KMT2D and ZFHX3 were the most mutated genes. Further, PIK3CA, BRCA1, BRCA2, ATM and TP53 gene loci had a higher frequency of CNVs. Moreover, the role of PIK3CA in cervical cancer was further highlighted by comparing with the ONCOKB database, especially for E545K and E542K, which were reported to confer radioresistance to cervical cancer. Notably, analysis of potential therapeutic targets suggested that cervical cancer patients could benefit from PARP inhibitors. This multigene NGS analysis revealed several novel genetic alterations in Chinese patients with cervical cancer and highlighted the role of PIK3CA in cervical cancer. Overall, this study showed that genetic variations not only affect the genetic susceptibility of cervical cancer, but also influence the resistance of cervical cancer to radiotherapy, but further studies involving a larger patient population should be undertaken to validate these findings.
Collapse
|
6
|
Kashofer K, Regauer S, Reich O, Petru E, Winter E. Driver gene mutations in micro-invasive cervical squamous cancers have no prognostic significance. Gynecol Oncol 2022; 165:121-128. [PMID: 35101299 DOI: 10.1016/j.ygyno.2022.01.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2021] [Revised: 01/12/2022] [Accepted: 01/14/2022] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To evaluate the prevalence of somatic gene mutations in different stages of cervical carcinogenesis placing special emphasis on micro-invasive pT1a cervical squamous cell cancers (SCC). METHODS Micro-dissected samples of 32 micro-invasive pT1a and 55 ≥ pT1b SCC were evaluated by next generation sequencing of 50 cancer genes (cancer hot spot panel). RESULTS At primary diagnosis, 8/32 (25%) pT1a SCC, 10/28 (36%) pT1b SCC and 15/27 (56%) pT2/3 SCC carried somatic gene mutations. The most commonly affected gene was the PIK3CA gene in hot spot regions E545K and E453K in 5/8 (62%) pT1a SCC, 7/15 (70%) pT1b SCC and 10/15 (66%) pT2/3 SCC followed by FBXW7 (n = 4), KRAS and RB1 (n = 2 each). ERBB2, APC, ATM, MLP gene mutations occurred only once. Solitary activating oncogenic somatic mutations dominated over tumor suppressor mutation in 88% pT1a, 80% pT1b and 60% pT2/3 SCC. Concomitant mutations involved typically an activating oncogenic mutation and an inactivating tumor-suppressor gene mutation. All patients with pT1a SCC are alive without evidence of disease after surgical treatment, independent of mutational status or lympho-vascular space invasion. CONCLUSIONS Activating oncogenic gene mutations, in particular in the PIK3CA gene, occur early in cervical carcinogenesis. Although driver gene mutations bestow tumor cells with a growth advantage, early detection and complete removal of all cancer cells - with or without somatic gene mutations - are essential for cure. In contrast to advanced inoperable SCC, where PIK3CA driver gene mutations carry an adverse prognosis, the mutational status in surgically treated micro-invasive SCC is prognostically irrelevant.
Collapse
Affiliation(s)
- Karl Kashofer
- Diagnostic- and Research Institute of Pathology, Medical University Graz, Neue Stiftingtalstrasse 6, 8010 Graz, Austria
| | - Sigrid Regauer
- Diagnostic- and Research Institute of Pathology, Medical University Graz, Neue Stiftingtalstrasse 6, 8010 Graz, Austria.
| | - Olaf Reich
- Department of Gynecology and Obstetrics, Medical University Graz, Auenbruggerplatz 14, 8036 Graz, Austria
| | - Edgar Petru
- Department of Gynecology and Obstetrics, Medical University Graz, Auenbruggerplatz 14, 8036 Graz, Austria
| | - Elke Winter
- Diagnostic- and Research Institute of Pathology, Medical University Graz, Neue Stiftingtalstrasse 6, 8010 Graz, Austria
| |
Collapse
|
7
|
Nilsen A, Hillestad T, Skingen VE, Aarnes E, Fjeldbo CS, Hompland T, Evensen TS, Stokke T, Kristensen GB, Grallert B, Lyng H. miR-200a/b/-429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer. Mol Oncol 2022; 16:1402-1419. [PMID: 35064630 PMCID: PMC8936520 DOI: 10.1002/1878-0261.13184] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2021] [Revised: 12/21/2021] [Accepted: 01/19/2022] [Indexed: 11/07/2022] Open
Abstract
Many patients with locally advanced cervical cancer experience recurrence within the radiation field after chemoradiotherapy. Biomarkers of tumor radioresistance are required to identify patients in need of intensified treatment. Here, the biomarker potential of miR-200 family members was investigated in this disease. Also, involvement of tumor hypoxia in the radioresistance mechanism was determined, using a previously defined 6-gene hypoxia classifier. miR-200 expression was measured in pre-treatment tumor biopsies of an explorative cohort (n=90) and validation cohort 1 (n=110) by RNA sequencing. Publicly available miR-200 data of 79 patients were included for validation of prognostic significance. A score based on expression of the miR-200a/b/-429 (miR-200a, miR-200b and miR-429) cluster showed prognostic significance in all cohorts. The score was significant in multivariate analysis of central pelvic recurrence. No association with distant recurrence or hypoxia status was found. Potential miRNA target genes were identified from gene expression profiles and showed enrichment of genes in extracellular matrix organization and cell adhesion. miR-200a/b/-429 overexpression had a pronounced radiosensitizing effect in tumor xenografts, whereas the effect was minor in vitro. In conclusion, miR-200a/b/-429 downregulation is a candidate biomarker of central pelvic recurrence and seems to predict cell-adhesion-mediated tumor radioresistance independent of clinical markers and hypoxia.
Collapse
Affiliation(s)
- Anja Nilsen
- Department of Radiation BiologyNorwegian Radium HospitalOslo University HospitalNorway
| | - Tiril Hillestad
- Department of Core FacilitiesNorwegian Radium HospitalOslo University HospitalNorway
| | - Vilde E. Skingen
- Department of Radiation BiologyNorwegian Radium HospitalOslo University HospitalNorway
| | - Eva‐Katrine Aarnes
- Department of Radiation BiologyNorwegian Radium HospitalOslo University HospitalNorway
| | - Christina S. Fjeldbo
- Department of Radiation BiologyNorwegian Radium HospitalOslo University HospitalNorway
| | - Tord Hompland
- Department of Radiation BiologyNorwegian Radium HospitalOslo University HospitalNorway
- Department of Core FacilitiesNorwegian Radium HospitalOslo University HospitalNorway
| | - Tina Sandø Evensen
- Department of Core FacilitiesNorwegian Radium HospitalOslo University HospitalNorway
| | - Trond Stokke
- Department of Core FacilitiesNorwegian Radium HospitalOslo University HospitalNorway
| | - Gunnar B. Kristensen
- Department of Gynecological OncologyNorwegian Radium HospitalOslo University HospitalNorway
- Institute of Cancer Genetics and InformaticsOslo University HospitalNorway
| | - Beata Grallert
- Department of Radiation BiologyNorwegian Radium HospitalOslo University HospitalNorway
| | - Heidi Lyng
- Department of Radiation BiologyNorwegian Radium HospitalOslo University HospitalNorway
- Department of PhysicsUniversity of OsloNorway
| |
Collapse
|
8
|
TP53 mutants and non-HPV16/18 genotypes are poor prognostic factors for concurrent chemoradiotherapy in locally advanced cervical cancer. Sci Rep 2021; 11:19261. [PMID: 34584128 PMCID: PMC8478905 DOI: 10.1038/s41598-021-98527-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2021] [Accepted: 09/08/2021] [Indexed: 12/20/2022] Open
Abstract
Targeted sequencing for somatic mutations across the hotspots of 50 cancer-related genes was performed using biopsy specimens to investigate whether clinicopathological factors and genomic alterations correlated with prognosis in locally advanced cervical cancer. Seventy patients diagnosed with International Federation of Obstetrics and Gynecology (FIGO) stage III to IVA cervical cancer underwent radiotherapy or concurrent chemoradiotherapy at the National Cancer Center Hospital between January 2008 and December 2017. Mutations were detected in 47 of 70 [67% of cases; frequency of genetic alterations was as follows: PIK3CA (51%), FBXW7 (10%), PTEN (7.1%), and TP53 (5.7%)]. The Cancer Genome Atlas (TCGA) datasets showed a similar distribution of somatic mutations, but PIK3CA mutation frequency was significantly higher in our cohort than in TCGA datasets (P = 0.028). Patients with TP53 mutation were significantly related to poor progression-free survival (PFS) (hazard ratio [HR] = 3.53, P = 0.042). Patients with tumor diameters > 70 mm were associated with poor prognosis (HR = 2.96, P = 0.0048). Patients with non-HPV16/18 genotypes had worse prognosis than those with HPV16/18 genotypes (HR = 2.15, P = 0.030). Hence, patients with locally advanced cervical cancer, TP53 mutation, large tumor diameter, and non-HPV16/18 genotype were independently correlated with poor PFS, despite concurrent chemoradiotherapy.
Collapse
|
9
|
Zheng Y, Xie L, Xu S, Yan W, Zhang H, Meng Y, Liu J, Wei X. Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial-mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K/Akt/mTOR signaling pathway activation. Mol Cell Biochem 2021; 476:4031-4044. [PMID: 34244973 DOI: 10.1007/s11010-021-04211-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2021] [Accepted: 06/16/2021] [Indexed: 01/30/2023]
Abstract
To explore the mechanism of miR-202-5p targeting the expression of PIK3CA and mediating the activation of PI3K/Akt/mTOR signaling pathway on the proliferation, invasion, and epithelial-mesenchymal transition (EMT) of cervical cancer. The objects of study were 105 cases of cervical cancer and their corresponding normal tissues. qRT-PCR was used to detect the expression of miR-202-5p and PIK3CA in adjacent normal tissue and cervical cancer tissue. Dual luciferase reporter assay was used to verify the targeting relationship between miR-202-5p and PIK3CA gene. Human cervical cancer cell lines HPV-16E6, SiHa, HeLa, and CaSki were purchased for our cell experiments. The expression levels of PIK3CA in the cells were detected by qRT-PCR. The cell line with higher expression levels was selected to complete the follow-up experiment. The cultured cells were transfected and divided into the miR-202-5p mimic NC group, miR-202-5p mimic group, miR-202-5p inhibitor NC group, miR-202-5p inhibitor group, siRNA-PIK3CA NC group, siRNA-PIK3CA group, miR-202-5p inhibitor NC + siRNA-PIK3CA NC group, miR-202-5p inhibitor + siRNA-PIK3CA NC group, and miR-202-5p inhibitor + siRNA-PIK3CA group. QRT-PCR was used to detect the expression of miR-202-5p. Western blot and qRT-PCR were applied to detect the mRNA and protein expression levels of related pathway proteins (PIK3CA, PI3K, PTEN, p-Akt1, and p-mTOR) and epithelial-mesenchymal transition-related factors (N-cadherin, E-cadherin, and vimentin). Cell proliferation was detected by plate colony formation assay. Transwell assay was used to detect the invasion ability of each group. When compared with the adjacent tissues, PIK3CA mRNA expression level was significantly increased and miR-202-5p expression level was significantly decreased in cervical cancer tissues (all P < 0.05). PIK3CA was a target gene of miR-202-5p. The mRNA expression level of PIK3CA in SiHa cervical cancer cells was significantly higher than that in CaSki, HeLa, and HPV-16E6 cells (all P < 0.05), and SiHa cervical cancer cells were selected to complete the follow-up experiments. When compared with the corresponding NC group, the expression of miR-202-5p in miR-202-5p mimic group was increased. In addition, the mRNA and protein expression levels of E-cadherin and PTEN in miR-202-5p mimic and siRNA-PIK3CA groups were increased, and the protein expression of p-Akt1 and p-mTOR was decreased, and also, the mRNA and protein expression levels of PIK3CA, PI3K, N-cadherin, and vimentin were decreased (all P < 0.05); in miR-202-5p inhibitor group, the expression levels of miR-202-5p, E-cadherin, and PTEN decreased, the protein expression of p-Akt1 and p-mTOR increased, and the mRNA and protein expression of PIK3CA, PI3K, N-cadherin, and vimentin increased in miR-202-5p inhibitor group (all P < 0.05); in miR-202-5p inhibitor + siRNA-PIK3CA group, the expression of miR-202-5p decreased (P < 0.05), but the mRNA and protein expression of PIK3CA, PI3K, p-Akt1, p-mTOR, N-cadherin, E-cadherin, and vimentin had no significant changes (all P > 0.05). When compared with the corresponding NC group, the number of cell clones in miR-202-5p mimic group and siRNA-PIK3CA group was decreased, and the invasion ability of miR-202-5p inhibitor group was increased, and the invasion ability was enhanced (all P < 0.05); miR-202-5p inhibitor + siRNA-PIK3CA group showed no significant change in the number of cell clones and the rate of invasion (P > 0.05). In conclusion, the overexpression of miR-202-5p can suppress PIK3CA gene expression and the activation of PI3K/Akt/mTOR signaling pathway to suppress the proliferation, invasion, and EMT of cervical cancer.
Collapse
Affiliation(s)
- Yan Zheng
- Department of Gynecology and Obstetrics, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Yuhua District, Shijiazhuang City, 050031, Hebei Province, People's Republic of China
| | - Lei Xie
- Department of Gynecology and Obstetrics, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Yuhua District, Shijiazhuang City, 050031, Hebei Province, People's Republic of China
| | - Shuwen Xu
- Department of Gynecology and Obstetrics, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Yuhua District, Shijiazhuang City, 050031, Hebei Province, People's Republic of China
| | - Weidong Yan
- Training & Research Support Center, Shijiazhuang Camps of the Army Engineering University, Shijiazhuang City, 050031, Hebei Province, People's Republic of China
| | - Hongzhen Zhang
- Department of Gynecology and Obstetrics, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Yuhua District, Shijiazhuang City, 050031, Hebei Province, People's Republic of China
| | - Yali Meng
- Department of Gynecology and Obstetrics, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Yuhua District, Shijiazhuang City, 050031, Hebei Province, People's Republic of China
| | - Jingqiao Liu
- Department of Gynecology and Obstetrics, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Yuhua District, Shijiazhuang City, 050031, Hebei Province, People's Republic of China.
| | - Xujing Wei
- Department of Gynecology and Obstetrics, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Yuhua District, Shijiazhuang City, 050031, Hebei Province, People's Republic of China.
| |
Collapse
|
10
|
Chung TKH, Doran G, Cheung TH, Yim SF, Yu MY, Worley MJ, Elias KM, Thorner AR, Pedamallu CS, Ojesina AI, Lau KM, Ducar MD, Wong RRY, Wang VW, Nag A, Wollison BM, Dalgarno A, Lee JHS, Yeung SY, Wong L, Horowitz NS, Davis MR, Leung SOA, Mu Y, Mok SC, Chan PKS, Lawrence MS, Crum CP, Chiu RWK, Berkowitz RS, Wong YF. Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes. Cancers (Basel) 2021; 13:cancers13133218. [PMID: 34203201 PMCID: PMC8269188 DOI: 10.3390/cancers13133218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Revised: 06/07/2021] [Accepted: 06/15/2021] [Indexed: 11/17/2022] Open
Abstract
Simple Summary There is limited information about genomic markers, especially for cervical adenocarcinoma treatment decisions. In this prospective study, it was found that nonsynonymous PIK3CA mutation detected in the patient’s circulating DNA collected before treatment or during follow-up was significantly associated with decreased progression-free survival or overall survival. It is the first indication of the predictive power of PIK3CA aberration in cervical adenocarcinoma. The work contributes to the development of liquid biopsies for the prolonged strategy of surveillance and indicates the possibility of tailoring management of this particular women’s cancer. Abstract Personalized treatment of genetically stratified subgroups has the potential to improve outcomes in many malignant tumors. This study distills clinically meaningful prognostic/predictive genomic marker for cervical adenocarcinoma using signature genomic aberrations and single-point nonsynonymous mutation-specific droplet digital PCR (ddPCR). Mutations in PIK3CA E542K, E545K, or H1047R were detected in 41.7% of tumors. PIK3CA mutation detected in the patient’s circulating DNA collected before treatment or during follow-up was significantly associated with decreased progression-free survival or overall survival. PIK3CA mutation in the circulating DNA during follow-up after treatment predicted recurrence with 100% sensitivity and 64.29% specificity. It is the first indication of the predictive power of PIK3CA mutations in cervical adenocarcinoma. The work contributes to the development of liquid biopsies for follow up surveillance and a possibility of tailoring management of this particular women’s cancer.
Collapse
Affiliation(s)
- Tony K. H. Chung
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong; (T.-H.C.); (S.-F.Y.); (M.-Y.Y.); (K.-M.L.); (R.R.Y.W.); (J.H.S.L.); (S.-Y.Y.); (L.W.); (P.K.S.C.); (R.W.K.C.)
- Correspondence: (T.K.H.C.); (R.S.B.); (Y.-F.W.); Tel.: +852-3505-2806 (T.K.H.C.); +1-617-732-8840 (R.S.B.); +852-3505-2806 (Y.-F.W.)
| | - Graeme Doran
- Firefly Bioworks, Inc., Cambridge, MA 02139, USA;
| | - Tak-Hong Cheung
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong; (T.-H.C.); (S.-F.Y.); (M.-Y.Y.); (K.-M.L.); (R.R.Y.W.); (J.H.S.L.); (S.-Y.Y.); (L.W.); (P.K.S.C.); (R.W.K.C.)
| | - So-Fan Yim
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong; (T.-H.C.); (S.-F.Y.); (M.-Y.Y.); (K.-M.L.); (R.R.Y.W.); (J.H.S.L.); (S.-Y.Y.); (L.W.); (P.K.S.C.); (R.W.K.C.)
| | - Mei-Yung Yu
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong; (T.-H.C.); (S.-F.Y.); (M.-Y.Y.); (K.-M.L.); (R.R.Y.W.); (J.H.S.L.); (S.-Y.Y.); (L.W.); (P.K.S.C.); (R.W.K.C.)
| | - Michael J. Worley
- Harvard Medical School, Brigham and Women’s Hospital, Boston, MA 02115, USA; (M.J.W.J.); (K.M.E.); (N.S.H.); (M.R.D.); (S.-O.A.L.); (Y.M.); (C.P.C.)
| | - Kevin M. Elias
- Harvard Medical School, Brigham and Women’s Hospital, Boston, MA 02115, USA; (M.J.W.J.); (K.M.E.); (N.S.H.); (M.R.D.); (S.-O.A.L.); (Y.M.); (C.P.C.)
| | - Aaron R. Thorner
- Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA; (A.R.T.); (C.S.P.); (M.D.D.); (A.N.); (B.M.W.); (A.D.)
| | - Chandra Sekhar Pedamallu
- Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA; (A.R.T.); (C.S.P.); (M.D.D.); (A.N.); (B.M.W.); (A.D.)
- Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA;
| | - Akinyemi I. Ojesina
- Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA;
| | - Kei-Man Lau
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong; (T.-H.C.); (S.-F.Y.); (M.-Y.Y.); (K.-M.L.); (R.R.Y.W.); (J.H.S.L.); (S.-Y.Y.); (L.W.); (P.K.S.C.); (R.W.K.C.)
| | - Matthew D. Ducar
- Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA; (A.R.T.); (C.S.P.); (M.D.D.); (A.N.); (B.M.W.); (A.D.)
| | - Raymond R. Y. Wong
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong; (T.-H.C.); (S.-F.Y.); (M.-Y.Y.); (K.-M.L.); (R.R.Y.W.); (J.H.S.L.); (S.-Y.Y.); (L.W.); (P.K.S.C.); (R.W.K.C.)
| | | | - Anwesha Nag
- Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA; (A.R.T.); (C.S.P.); (M.D.D.); (A.N.); (B.M.W.); (A.D.)
| | - Bruce M. Wollison
- Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA; (A.R.T.); (C.S.P.); (M.D.D.); (A.N.); (B.M.W.); (A.D.)
| | - Audrey Dalgarno
- Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA; (A.R.T.); (C.S.P.); (M.D.D.); (A.N.); (B.M.W.); (A.D.)
| | - Jacqueline H. S. Lee
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong; (T.-H.C.); (S.-F.Y.); (M.-Y.Y.); (K.-M.L.); (R.R.Y.W.); (J.H.S.L.); (S.-Y.Y.); (L.W.); (P.K.S.C.); (R.W.K.C.)
| | - Suet-Ying Yeung
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong; (T.-H.C.); (S.-F.Y.); (M.-Y.Y.); (K.-M.L.); (R.R.Y.W.); (J.H.S.L.); (S.-Y.Y.); (L.W.); (P.K.S.C.); (R.W.K.C.)
| | - Lo Wong
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong; (T.-H.C.); (S.-F.Y.); (M.-Y.Y.); (K.-M.L.); (R.R.Y.W.); (J.H.S.L.); (S.-Y.Y.); (L.W.); (P.K.S.C.); (R.W.K.C.)
| | - Neil S. Horowitz
- Harvard Medical School, Brigham and Women’s Hospital, Boston, MA 02115, USA; (M.J.W.J.); (K.M.E.); (N.S.H.); (M.R.D.); (S.-O.A.L.); (Y.M.); (C.P.C.)
| | - Michelle R. Davis
- Harvard Medical School, Brigham and Women’s Hospital, Boston, MA 02115, USA; (M.J.W.J.); (K.M.E.); (N.S.H.); (M.R.D.); (S.-O.A.L.); (Y.M.); (C.P.C.)
| | - Shuk-On A. Leung
- Harvard Medical School, Brigham and Women’s Hospital, Boston, MA 02115, USA; (M.J.W.J.); (K.M.E.); (N.S.H.); (M.R.D.); (S.-O.A.L.); (Y.M.); (C.P.C.)
| | - Yi Mu
- Harvard Medical School, Brigham and Women’s Hospital, Boston, MA 02115, USA; (M.J.W.J.); (K.M.E.); (N.S.H.); (M.R.D.); (S.-O.A.L.); (Y.M.); (C.P.C.)
| | - Samuel C. Mok
- MD Anderson Cancer Center, The University of Texas, Houston, TX 77030, USA;
| | - Paul K. S. Chan
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong; (T.-H.C.); (S.-F.Y.); (M.-Y.Y.); (K.-M.L.); (R.R.Y.W.); (J.H.S.L.); (S.-Y.Y.); (L.W.); (P.K.S.C.); (R.W.K.C.)
| | - Michael S. Lawrence
- Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA;
- Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Christopher P. Crum
- Harvard Medical School, Brigham and Women’s Hospital, Boston, MA 02115, USA; (M.J.W.J.); (K.M.E.); (N.S.H.); (M.R.D.); (S.-O.A.L.); (Y.M.); (C.P.C.)
| | - Rossa W. K. Chiu
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong; (T.-H.C.); (S.-F.Y.); (M.-Y.Y.); (K.-M.L.); (R.R.Y.W.); (J.H.S.L.); (S.-Y.Y.); (L.W.); (P.K.S.C.); (R.W.K.C.)
| | - Ross S. Berkowitz
- Harvard Medical School, Brigham and Women’s Hospital, Boston, MA 02115, USA; (M.J.W.J.); (K.M.E.); (N.S.H.); (M.R.D.); (S.-O.A.L.); (Y.M.); (C.P.C.)
- Correspondence: (T.K.H.C.); (R.S.B.); (Y.-F.W.); Tel.: +852-3505-2806 (T.K.H.C.); +1-617-732-8840 (R.S.B.); +852-3505-2806 (Y.-F.W.)
| | - Yick-Fu Wong
- The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong; (T.-H.C.); (S.-F.Y.); (M.-Y.Y.); (K.-M.L.); (R.R.Y.W.); (J.H.S.L.); (S.-Y.Y.); (L.W.); (P.K.S.C.); (R.W.K.C.)
- Harvard Medical School, Brigham and Women’s Hospital, Boston, MA 02115, USA; (M.J.W.J.); (K.M.E.); (N.S.H.); (M.R.D.); (S.-O.A.L.); (Y.M.); (C.P.C.)
- Correspondence: (T.K.H.C.); (R.S.B.); (Y.-F.W.); Tel.: +852-3505-2806 (T.K.H.C.); +1-617-732-8840 (R.S.B.); +852-3505-2806 (Y.-F.W.)
| |
Collapse
|
11
|
Patrono MG, Calvo MF, Franco JVA, Garrote V, Vietto V. A systematic review and meta-analysis of the prevalence of therapeutic targets in cervical cancer. Ecancermedicalscience 2021; 15:1200. [PMID: 33889209 PMCID: PMC8043690 DOI: 10.3332/ecancer.2021.1200] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2020] [Indexed: 02/04/2023] Open
Abstract
Cervical Cancer (CC) is a significantly prevalent disease in developing countries. Currently, targeted therapies are not a primary standard of care in CC. This information could be crucial for developing directed therapies and patient screening for biomarkers that would allow personalised treatment of CC. This systematic review aimed to estimate the prevalence of potential therapeutic targets such as the epidermal growth factor receptor (EGFR) and the PI3K/Akt/mTOR and Ras/Raf/MAPK pathways in patients with CC, identified through genomic and non-genomic testing. Studies were identified through an ad-hoc search strategy from the available on MEDLINE (Ovid), CENTRAL, LILACS, SCOPUS, through the Clinical Trial registry on Clinicaltrials.gov, International Clinical Trials Registry Platform, RENIS (Argentine National Registry of Health Research) and grey literature sources. We included 74 studies which represented a total pool of 7,862 participants. Forty-five studies informed mutations of EGFR, with a combined positivity rate of 53% (95%CI: 45%-60%; I2 = 95%). Twenty studies informed the presence of mutations in PIK3CA with a combined positivity rate of 30% (95%CI: 21%-39%; I2 = 96%). Twenty-three studies reported a mutation in Ras, with a combined positivity rate of 14% (95%CI: 8%-21%; I2 = 95%). Raf mutations were informed in six studies. Six studies informed the presence of Akt mutations, two studies informed mTOR mutations and only one study reported mutations of MAPK. The most frequently described therapeutic targets were EGFR, and the PIK3CA and Ras pathways, though inconsistency in positivity rates was significant. Our study did not allow the identification of any specific clinical characteristics that might explain the observed heterogeneity. Despite the overall good quality of the included studies, the applicability of these results to patients' general population with CC is still unclear.
Collapse
Affiliation(s)
- Maria Guadalupe Patrono
- Department of Gynecology, Hospital Italiano de Buenos Aires, Gascon 450, Buenos Aires C1181ACH, Argentina
- https://orcid.org/0000-0002-1309-2114
| | - Maria Florencia Calvo
- Department of Gynecology, Hospital Italiano de Buenos Aires, Gascon 450, Buenos Aires C1181ACH, Argentina
- https://orcid.org/0000-0002-2224-1564
| | - Juan Victor Ariel Franco
- Family and Community Medicine Division, Hospital Italiano de Buenos Aires, Gascon 450, Buenos Aires C1181ACH, Argentina
- Argentine Cochrane Centre, Instituto Universitario Hospital Italiano, Potosí 4265, Buenos Aires C1199ABB, Argentina
- https://orcid.org/0000-0003-0411-899X
| | - Virginia Garrote
- Central Library, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, Tte. J. D. Perón 4190, 1º floor, stair J. C1199ABB, Argentina
- https://orcid.org/0000-0002-7328-6228
| | - Valeria Vietto
- Family and Community Medicine Division, Hospital Italiano de Buenos Aires, Gascon 450, Buenos Aires C1181ACH, Argentina
- Argentine Cochrane Centre, Instituto Universitario Hospital Italiano, Potosí 4265, Buenos Aires C1199ABB, Argentina
- https://orcid.org/0000-0003-4619-9812
| |
Collapse
|
12
|
Pergialiotis V, Nikolaou C, Haidopoulos D, Frountzas M, Thomakos N, Bellos I, Papapanagiotou A, Rodolakis A. PIK3CA Mutations and Their Impact on Survival Outcomes of Patients with Cervical Cancer: A Systematic Review. Acta Cytol 2020; 64:547-555. [PMID: 32683364 DOI: 10.1159/000509095] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2020] [Accepted: 05/28/2020] [Indexed: 01/17/2023]
Abstract
INTRODUCTION Several studies have implicated the PIK3/AKT pathway in the pathophysiology of cancer progression as its activation seems to be aberrant in several forms of cancer. The purpose of the present systematic review is to evaluate the impact of PIK3CA mutations on survival outcomes of patients with cervical cancer. METHODS We used the Medline (1966-2020), Scopus (2004-2020), ClinicalTrials.gov (2008-2020), EMBASE (1980-2020), Cochrane Central Register of Controlled Trials (CENTRAL) (1999-2020), and Google Scholar (2004-2020) databases in our primary search along with the reference lists of electronically retrieved full-text papers. Statistical meta-analysis was performed with the RevMan 5.3 software. RESULTS Overall, 12 articles were included in the present study that comprised 2,196 women with cervical cancer. Of those, 3 studies did not report significant differences in survival outcomes among patients with mutated versus wild-type PIK3CA tumors, 5 studies reported decreased survival outcomes, and 3 studies revealed increased survival rates. The meta-analysis revealed that patients with the mutated PIK3CA genotypes had worse overall survival compared to patients with wild-type PIK3CA (HR 2.31; 95% CI: 1.51, 3.55; 95% PI: 0.54, 9.96; data from 3 studies) and the same was observed in the case of DFS rates (HR 1.82; 95% CI: 1.47, 2.25; 95% PI: 1.29, 2.56; data from 4 studies). CONCLUSION Current evidence concerning the impact of PIK3CA mutations on survival outcomes of patients with cervical cancer is inconclusive, although the majority of included studies support a potential negative effect, primarily among those with squamous cell carcinoma tumors.
Collapse
Affiliation(s)
- Vasilios Pergialiotis
- Laboratory of Experimental Surgery and Surgical Research N.S Christeas, National and Kapodistrian University of Athens, Athens, Greece,
- 1st Department of Obstetrics and Gynecology, Attikon Hospital, National and Kapodistrian University of Athens, Athens, Greece,
| | - Christina Nikolaou
- Laboratory of Experimental Surgery and Surgical Research N.S Christeas, National and Kapodistrian University of Athens, Athens, Greece
| | - Dimitrios Haidopoulos
- 1st Department of Obstetrics and Gynecology, Attikon Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - Maximos Frountzas
- Laboratory of Experimental Surgery and Surgical Research N.S Christeas, National and Kapodistrian University of Athens, Athens, Greece
| | - Nikolaos Thomakos
- Laboratory of Experimental Surgery and Surgical Research N.S Christeas, National and Kapodistrian University of Athens, Athens, Greece
| | - Ioannis Bellos
- Laboratory of Experimental Surgery and Surgical Research N.S Christeas, National and Kapodistrian University of Athens, Athens, Greece
| | - Angeliki Papapanagiotou
- Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece
| | - Alexandros Rodolakis
- 1st Department of Obstetrics and Gynecology, Attikon Hospital, National and Kapodistrian University of Athens, Athens, Greece
| |
Collapse
|
13
|
Li X, Zhang Y, Walana W, Zhao F, Li F, Luo F. GDC-0941 and CXCL8 (3-72) K11R/G31P combination therapy confers enhanced efficacy against breast cancer. Future Oncol 2020; 16:911-921. [PMID: 32285685 DOI: 10.2217/fon-2020-0035] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Aim: Herein is presented the combined effect of PI3K inhibitor (GDC-0941) and CXCR1/2 analogue (G31P) in breast cancer. Materials & methods: Breast cancer cell lines and xenograft model were employed to test the efficacy of the combination therapy. Results: GDC-0941+G31P treatment substantially inhibited multiplication of all the breast cancer cell lines used in this study (BT474, HCC1954 and 4T1). Even though single therapies caused a meaningful S-phase cell cycle arrest, the inhibition effect was more potent with the combined treatment. Similarly, enhanced apoptosis accompanied GDC-0941+G31P treatment. Furthermore, the migration ability of the breast cancer cell lines were significantly curtailed by the combination therapy compared with the single treatments. Conclusion: The findings suggest that combination treatment involving PI3K inhibitor and CXCR1/2 analogue (G31P) could be a potent therapeutic option for breast cancer treatment.
Collapse
Affiliation(s)
- Xiaodong Li
- Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, 116044, Liaoning, PR China
| | - Yuanyue Zhang
- Department of Immunology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, Liaoning, PR China
| | - Williams Walana
- Department of Immunology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, Liaoning, PR China.,Department of Clinical Microbiology, University for Development Studies, Tamale, Ghana
| | - Feng Zhao
- College of Basic Medical Science, Dalian Medical University, #9 West Section Lvshun South Road, Dalian, 116044, Liaoning, PR China
| | - Fang Li
- Department of Immunology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, Liaoning, PR China
| | - Fuwen Luo
- Department of Acute Abdominal Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116044, Liaoning, PR China
| |
Collapse
|
14
|
PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis. Cancers (Basel) 2019; 12:cancers12010093. [PMID: 31905960 PMCID: PMC7017171 DOI: 10.3390/cancers12010093] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2019] [Revised: 12/18/2019] [Accepted: 12/19/2019] [Indexed: 02/07/2023] Open
Abstract
Phosphoinositide kinases (PIKs) are a group of lipid kinases that are important upstream activators of various significant signaling pathways. Hyperactivation of the PI3K/AKT/mTOR pathways—either via mutations or genomic amplification—confers key oncogenic activity, essential for the development and progression of several solid tumors. Alterations in the PIK3CA gene are associated with poor prognosis of solid malignancies. Although the literature reports contradictory prognostic values of PIK3CA in aggressive cancers, most of the available data highlight the important role of PIK3CA mutation in mediating tumorigenesis via increased signaling of the PI3K/AKT/mTOR survival pathway. Several inhibitors of PI3K/AKT/mTOR pathways are investigated as potential therapeutic options in solid malignancies. This article reviews the role of PIK3CA mutations and inhibitors of PI3K/AKT/mTOR pathways in major cancer types and examines its association with clinicopathological parameters and prognosis.
Collapse
|
15
|
Xu X, Jiang X, Chen L, Zhao Y, Huang Z, Zhou H, Shi M. MiR-181a Promotes Apoptosis and Reduces Cisplatin Resistance by Inhibiting Osteopontin in Cervical Cancer Cells. Cancer Biother Radiopharm 2019; 34:559-565. [PMID: 31436472 DOI: 10.1089/cbr.2019.2858] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Objective: In this study, the authors established a cervical cancer cisplatin (DDP) drug-resistant cell line to explore the role of miR-181a in the regulation of osteopontin (OPN) expression and the proliferation, apoptosis, as well as DDP resistance of cervical cancer cells. Materials and Methods: Dual luciferase reporter gene assay was performed to validate the targeted relationship between miR-181a and OPN. The DDP-resistant cell line CaSki/DDP was established to compare the expressions of miR-181a and OPN. The cell proliferation activity was detected by CCK-8 assay. CaSki/DDP cells were divided into miR-NC group and miR-181a mimic group followed by analysis of cell apoptosis by flow cytometry, and the cell proliferation by EdU staining. Results: There was a targeted relationship between miR-181a and OPN mRNA. MiR-181a expression was significantly lower, while OPN mRNA and protein levels were significantly higher in CaSki/DDP cells than that in CaSki cells. Compared with the miR-NC group, OPN mRNA and protein were significantly decreased, cell apoptosis was significantly increased, and cell proliferation ability was significantly attenuated in miR-181a mimic transfection group. Conclusions: The decrease of miR-181a expression and the upregulation of OPN expression are related to the DDP resistance of cervical cancer cells. Overexpression of miR-181a can inhibit the expression of OPN, induce cell apoptosis cells, restrain cell proliferation, and reduce DDP resistance in cervical cancer cells.
Collapse
Affiliation(s)
- Xiaofei Xu
- Department of Obstetrics and Gynecology, Lishui Hospital of Traditional Chinese Medicine, Lishui, Zhejiang, China
| | - Xiaofei Jiang
- Department of Gynecology, Xuzhou Hospital of Traditional Chinese Medicine, Xuzhou, Jiangsu, China
| | - Liping Chen
- Department of Cardiology, Lishui Hospital of Traditional Chinese Medicine, Lishui, Zhejiang, China
| | - Yu Zhao
- Department of Obstetrics and Gynecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Zhihua Huang
- Department of Obstetrics and Gynecology, Lishui People's Hospital, Lishui, Zhejiang, China
| | - Huifang Zhou
- Department of Gynecology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
| | - Mingqing Shi
- Department of Obstetrics and Gynecology, Lishui Hospital of Traditional Chinese Medicine, Lishui, Zhejiang, China
| |
Collapse
|
16
|
Tantengco OAG, Nakura Y, Yoshimura M, Llamas-Clark EF, Yanagihara I. Association of PIK3CA and MDM2 SNP309 with Cervical Squamous Cell Carcinoma in a Philippine Population. Asian Pac J Cancer Prev 2019; 20:2103-2107. [PMID: 31350972 PMCID: PMC6745237 DOI: 10.31557/apjcp.2019.20.7.2103] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Indexed: 12/18/2022] Open
Abstract
Background: PIK3CA and MDM2 SNP309 have been studied to be associated with cervical cancer. PIK3CA mutation
is associated with poor treatment response and low survival rate while MDM2 is associated with tumorigenesis and
poor prognosis in cervical cancer. Thus, we determined the prevalence of PIK3CA and MDM2 mutations in Filipino
cervical cancer patients. Methods: Twenty-eight formalin-fixed paraffin-embedded cervical squamous cell carcinoma
and 16 non-malignant cervix tissue biopsies of Filipino patients were subjected to PIK3CA gene and MDM2 SNP309
(rs2279744) analysis. Results: PIK3CA gene was found mutated in three (10.71 %) out of 28 cervical cancer patients
included in this study. Among the HPV-negative cervical cancer patients, two (28.57 %) were positive for PIK3CA
mutation and only one (4.76 %) tested positive among the HPV-positive cervical cancer patients. MDM2 SNP309
analysis revealed that T allele (71.43%) was more common in cervical cancer patients compared to the control group.
TG genotype (p = 0.03; OR = 0.18, 95% CI 0.04-0.76) was associated with lower rates of cervical cancer when TT
genotype was used as a reference point. Conclusion: PIK3CA gene mutation was present among Filipino cervical
cancer patients and not in control patients. MDM2 SNP309 analysis revealed that TG genotype has lower association
to cervical cancer when compared with the TT and GG genotypes.
Collapse
Affiliation(s)
- Ourlad Alzeus G Tantengco
- College of Medicine, University of the Philippines Manila, Manila, Philippines.,Department of Developmental Medicine, Research Institute, Osaka Women's and Children's Hospital, Izumi, Osaka, Japan
| | - Yukiko Nakura
- Department of Developmental Medicine, Research Institute, Osaka Women's and Children's Hospital, Izumi, Osaka, Japan
| | - Michinobu Yoshimura
- Department of Developmental Medicine, Research Institute, Osaka Women's and Children's Hospital, Izumi, Osaka, Japan
| | - Erlidia F Llamas-Clark
- Department of Obstetrics and Gynecology, College of Medicine, University of the Philippines-Philippines General Hospital, Manila, Philippines.
| | - Itaru Yanagihara
- Department of Developmental Medicine, Research Institute, Osaka Women's and Children's Hospital, Izumi, Osaka, Japan
| |
Collapse
|
17
|
Bernardes-Oliveira E, Farias KJS, Gomes DL, de Araújo JMG, da Silva WD, Rocha HAO, Donadi EA, Fernandes-Pedrosa MDF, Crispim JCDO. Tityus serrulatus Scorpion Venom Induces Apoptosis in Cervical Cancer Cell Lines. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE : ECAM 2019; 2019:5131042. [PMID: 31341494 PMCID: PMC6612397 DOI: 10.1155/2019/5131042] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/11/2019] [Revised: 04/15/2019] [Accepted: 06/02/2019] [Indexed: 01/18/2023]
Abstract
Cervical cancer (CC) is classified as the fourth most common type of cancer in women worldwide and remains a serious public health problem in many underdeveloped countries. Human papillomavirus (HPV), mainly types 16 and 18, has been established as a precursory etiologic agent for this type of cancer. Several therapeutic attempts have been studied and applied, aiming at its control. However, not only do classical treatments such as chemotherapies and radiotherapies target tumor cells, but also they cause damage to several healthy cells. For these reasons, the search for new biologically active chemotherapeutic components is of great importance. In this study, we investigated the effect of Tityus serrulatus scorpion venom (TsV) on CC lines. There are very few studies exploring venom of scorpions, and, to our knowledge, no study has been conducted using the venom of the scorpion TsV for treatment of cervical cancer lines. After challenge with TsV, the MTT assay demonstrated cytotoxic effect on HeLa line. Similarly, the cell death process in HeLa analyzed by flow cytometry suggests death via caspase, since the pan-caspase inhibitor z-VAD-fmk significantly reduced the apoptotic response to the treatment. These results suggest that venom of TsV can be a potential source for the isolation of effective antiproliferative and apoptotic molecules in the treatment of CC.
Collapse
Affiliation(s)
- Emanuelly Bernardes-Oliveira
- Programa de Pós-Graduação em Desenvolvimento e Inovação Tecnológica em Medicamentos, Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil
| | - Kleber Juvenal Silva Farias
- Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil
| | - Dayanne Lopes Gomes
- Departamento de Bioquímica, Centro Biociências, Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil
| | - Josélio Maria Galvão de Araújo
- Departamento de Microbiologia e Parasitologia da Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil
- Laboratorio de Virologia, Instituto de Medicina Tropical, Universidade Federal do Rio Grande do Norte, RN, Brazil
| | | | | | - Eduardo Antônio Donadi
- Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Matheus de Freitas Fernandes-Pedrosa
- Programa de Pós-Graduação em Desenvolvimento e Inovação Tecnológica em Medicamentos, Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil
- Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil
| | - Janaina Cristiana de Oliveira Crispim
- Programa de Pós-Graduação em Desenvolvimento e Inovação Tecnológica em Medicamentos, Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil
- Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil
- Maternidade Escola Januário Cicco (MEJC), Natal, RN, Brazil
| |
Collapse
|
18
|
PI3K/AKT/mTOR Signaling Regulates the Virus/Host Cell Crosstalk in HPV-Positive Cervical Cancer Cells. Int J Mol Sci 2019; 20:ijms20092188. [PMID: 31058807 PMCID: PMC6539191 DOI: 10.3390/ijms20092188] [Citation(s) in RCA: 67] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2019] [Revised: 04/26/2019] [Accepted: 04/30/2019] [Indexed: 12/15/2022] Open
Abstract
Human papillomavirus (HPV)-induced cancers will remain a significant clinical challenge for decades. Thus, the development of novel treatment strategies is urgently required, which should benefit from improving our understanding of the mechanisms of HPV-induced cell transformation. This should also include analyses of hypoxic tumor cells, which represent a major problem for cancer therapy. Recent evidence indicates that the PI3K/AKT/mTOR network plays a key role for the virus/host cell crosstalk in both normoxic and hypoxic HPV-positive cancer cells. In normoxic cells, the efficacy of the senescence induction upon experimental E6/E7 repression depends on active mTORC1 signaling. Under hypoxia, however, HPV-positive cancer cells can evade senescence due to hypoxic impairment of mTORC1 signaling, albeit the cells strongly downregulate E6/E7. Hypoxic repression of E6/E7 is mediated by the AKT kinase, which is activated under hypoxia by its canonical upstream regulators mTORC2 and PI3K. This review highlights our current knowledge about the oxygen-dependent crosstalk of the PI3K/AKT/mTOR signaling circuit with the HPV oncogenes and the phenotypic state of the host cell. Moreover, since the PI3K/AKT/mTOR pathway is considered to be a promising target for anticancer therapy, we discuss clinical implications for the treatment of HPV-positive cervical and head and neck squamous cell carcinomas.
Collapse
|